ClinicalTrials.gg
RecruitingNCT05776082Updated Sep 3, 2026

Association of Gestational Cardiovascular Health With Pregnancy Outcomes

An observational study in Pregnant Women, sponsored by Women's Hospital School Of Medicine Zhejiang University. Recruiting at 3 sites in 2 countries. Open to female participants aged 20 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Women's Hospital School Of Medicine Zhejiang University · Observational

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
20 Years to 49 Years
Sex
Female
01

Study summary

Pregnancy is a critical period for cardiovascular health risk assessment and interventions to reduce the incidence of cardiovascular disease in both mother and child generations. Recently, the American Heart Association proposed the latest cardiovascular health assessment indicator "Life's Essential 8". However, there is still a lack of application data for pregnant women. This project intends to explore the application potential of Life's Essential 8 in cardiovascular health assessment of pregnant women and establish appropriate gestaional cardiovascular health standards.

02

Conditions studied

  • Pregnant Women
03

In context

Lead sponsor

Women's Hospital School Of Medicine Zhejiang University is the lead sponsor of 79 studies on the registry; 49 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 49 Years
Sexes eligible
Female
Sampling method
Probability sample

Study population

This project intends to recruit pregnant women who go to the research center for routine prenatal examination and give birth.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Maternal age: 20-49 years;
  • Natural conception;
  • Single pregnancy;
  • Plan to have routine prenatal examinations and give birth in the research center;

Exclusion criteria

Exclusion Criteria:

  • Have diseases that affect metabolic function or even threaten the life of the mother and fetus before pregnancy;
  • Assisted reproduction;
  • Multiple pregnancy;
  • Fetus has a known deformity or genetic defects;
  • Incomplete clinical data.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • OtherQuestionnaire survey and specimen collection

    Questionnaire survey, clinical follow-up and specimens collection.

06

What researchers measure

Primary outcomes

  1. Maternal outcomes

    Including pregnancy-induced hypertension, preterm delivery, abortion, delivery way and so on. They are diagnosed by clinicians and the data is gathered from medical records.

    Time frame: Through delivery completion, up to 42 weeks

  2. Neonatal outcomes

    Birth weight(in gram), birth height (in centimetre), gestational week (in week) and other neonatal diseases. They are diagnosed by clinicians and the data is gathered from medical records.

    Time frame: Through delivery completion, up to 42 weeks

07

Study locations

2 of 3 sites recruiting
  • Women's Hospital School Of Medicine Zhejiang University
    Hangzhou, Zhejiang 310006, China
    Recruiting
  • Taizhou First People's Hospital
    Taizhou, Zhejiang 310000, China
    Recruiting
  • Rwanda Society of Obstetricians and Gynecologists
    Kigali, Rwanda
    Active, not recruiting

    Not enrolling at this site.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05776082
Lead sponsor
Women's Hospital School Of Medicine Zhejiang University
Responsible party
Sponsor
First posted
Mar 20, 2023
Start date
Mar 1, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 3, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion